---
title: "Nurtec ODT (rimegepant) in acute treatment of migraine: Clinical trials questions"
description: "Clinical trials questions on Nurtec ODT (rimegepant) in acute treatment of migraine, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results. Questions: How was Nurtec ODT studied for acute migraine (trial 303)? How many patients were pain free 2 hours after Nurtec ODT vs placebo? Does Nurtec ODT relieve migraine pain at 2 hours vs placebo? How many patients stayed pain free 2 to 48 hours after Nurtec ODT? 3 further questions follow. 7 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine/clinical-trials"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nurtec ODT (rimegepant) in acute treatment of migraine: Clinical trials questions

Manufacturer: Pfizer Inc  
Prescribing information: [Nurtec ODT](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036)

Questions that apply to every indication of Nurtec ODT are on [Nurtec ODT (rimegepant), all indications](https://www.evicenter.com/medical-information/nurtec-odt).

## Study results

<a id="nurtec-pivotal-trial-design"></a>

### How was Nurtec ODT studied for acute migraine (trial 303)?

> “The efficacy of NURTEC ODT for the acute treatment of migraine with and without aura in adults was demonstrated in a randomized, double-blind, placebo-controlled trial: Study 1 (NCT03461757). Patients in the study were randomized to receive 75 mg of NURTEC ODT (N=732) or placebo (N=734). Patients were instructed to treat a migraine of moderate to severe headache pain intensity. Rescue medication (i.e., NSAIDs, acetaminophen, and/or an antiemetic) was allowed 2 hours after the initial treatment. Other forms of rescue medication such as triptans were not allowed within 48 hours of initial treatment. Approximately 14% of patients were taking preventive medications for migraine at baseline. None of the patients in Study 1 were on concomitant preventive medication that act on the CGRP pathway.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=The%20efficacy%20of%20NURTEC%20ODT,act%20on%20the%20CGRP%20pathway.)

> “The primary efficacy analyses were conducted in patients who treated a migraine with moderate to severe pain. NURTEC ODT 75 mg demonstrated an effect on pain freedom and most bothersome symptom (MBS) freedom at two hours after dosing, compared to placebo. Pain freedom was defined as a reduction of moderate or severe headache pain to no headache pain, and MBS freedom was defined as the absence of the self-identified MBS (i.e., photophobia, phonophobia, or nausea). Among patients who selected an MBS, the most commonly selected symptom was photophobia (54%), followed by nausea (28%), and phonophobia (15%).”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=The%20primary%20efficacy%20analyses%20were,nausea%20%2828%25%29%2C%20and%20phonophobia%20%2815%25%29.)

Note: The label calls this trial Study 1 (NCT03461757); the Nurtec HCP site calls it trial 303 and cites NCT03461757 for study BHV3000-303.

<a id="nurtec-pain-free-2-hours"></a>

### How many patients were pain free 2 hours after Nurtec ODT vs placebo?

> “In Study 1, the percentage of patients achieving headache pain freedom and MBS freedom two hours after a single dose was statistically significantly greater in patients who received NURTEC ODT compared to those who received placebo (Table 1).”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=In%20Study%201%2C%20the%20percentage,who%20received%20placebo%20%28Table%201%29.)

> “Table 1: Efficacy Endpoints for the Acute Treatment of Migraine in Study 1
> 	Study 1
> 	NURTEC ODT
> 75 mg	Placebo
>
> *
> n=number of responders/N=number of patients in that treatment group
>
>
>
> Pain Free at 2 hours
>
>
>
>
>   n/N*
>
>
>
> 142/669
>
>
>
> 74/682
>
>
>
>
>   % Responders
>
>
>
> 21.2
>
>
>
> 10.9
>
>
>
>
>   Difference from placebo (%)
>
>
>
> 10.3
>
>
>
>
>   p-value
>
>
>
> <0.001
>
>
>
>
> MBS Free at 2 hours
>
>
>
>
>   n/N*
>
>
>
> 235/669
>
>
>
> 183/682
>
>
>
>
>   % Responders
>
>
>
> 35.1
>
>
>
> 26.8
>
>
>
>
>   Difference from placebo (%)
>
>
>
> 8.3
>
>
>
>
>   p-value
>
>
>
> 0.001”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Table%201%3A%20Efficacy%20Endpoints%20for,0.001)

Note: Single 75 mg dose of Nurtec ODT compared with placebo in adults treating a migraine attack of moderate to severe pain (Study 1, NCT03461757). Table 1 columns are NURTEC ODT 75 mg and placebo, in that order. MBS is the most bothersome symptom (photophobia, phonophobia, or nausea).

<a id="nurtec-pain-relief-2-hours"></a>

### Does Nurtec ODT relieve migraine pain at 2 hours vs placebo?

> “In Study 1, statistically significant effects of NURTEC ODT compared to placebo were demonstrated for the additional efficacy endpoints of pain relief at 2 hours, sustained pain freedom 2-48 hours, use of rescue medication within 24 hours, and the percentage of patients reporting normal function at two hours after dosing (Table 2). Pain relief was defined as a reduction in migraine pain from moderate or severe severity to mild or none.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=In%20Study%201%2C%20statistically%20significant,severity%20to%20mild%20or%20none.)

> “Table 2: Additional Acute Treatment of Migraine Efficacy Endpoints in Study 1
> 	Study 1
> 	NURTEC ODT
> 75 mg	Placebo
>
> *
> n=number of responders/N=number of patients in that treatment group
> †
> This analysis includes only the use of NSAIDs, acetaminophen, or antiemetics, within 24 hours post-dose; the use of triptans, or other acute migraine medication, was not allowed.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Table%202%3A%20Additional%20Acute%20Treatment,migraine%20medication%2C%20was%20not%20allowed.)

> “Pain Relief at 2 hours
>
>
>
>
>     n/N*
>
>
>
> 397/669
>
>
>
> 295/682
>
>
>
>
>    % Responders
>
>
>
> 59.3
>
>
>
> 43.3
>
>
>
>
>    Difference from placebo
>
>
>
> 16.1
>
>
>
>
>    p-value
>
>
>
> <0.001”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=was%20not%20allowed.-,Pain%20Relief%20at%202%20hours,%3C0.001)

Note: Single 75 mg dose of Nurtec ODT compared with placebo in adults treating a migraine attack of moderate to severe pain (Study 1, NCT03461757). Table columns are NURTEC ODT 75 mg and placebo, in that order.

<a id="nurtec-sustained-pain-freedom"></a>

### How many patients stayed pain free 2 to 48 hours after Nurtec ODT?

> “Sustained Pain Freedom 2-48 hours
>
>
>
>
>    n/N*
>
>
>
> 90/669
>
>
>
> 37/682
>
>
>
>
>    % Responders
>
>
>
> 13.5
>
>
>
> 5.4
>
>
>
>
>    Difference from placebo
>
>
>
> 8.0
>
>
>
>
>   p-value
>
>
>
> <0.001”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=%3C0.001-,Sustained%20Pain%20Freedom%202%2D48%20hours,%3C0.001)

> “n=number of responders/N=number of patients in that treatment group”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=n%3Dnumber%20of%20responders%2FN%3Dnumber%20of%20patients%20in%20that%20treatment%20group)

Note: Single 75 mg dose of Nurtec ODT compared with placebo (Study 1, NCT03461757); the row is from Table 2 of the label, whose columns are NURTEC ODT 75 mg and placebo, in that order.

<a id="nurtec-rescue-medication"></a>

### How many patients needed rescue medication within 24 hours after Nurtec ODT?

> “86% of patients on Nurtec ODT did not need a rescue medication within 24 hours postdose (n=574/669) vs 71% on placebo (n=483/682); Δ15%# (P<0.0001) (select secondary endpoint)<sup>2,3</sup>”

Source: [NURTEC ODT: Acute Pivotal Trial, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-pivotal-trial#:~:text=86%25%20of%20patients%20on%20Nurtec,%28n%3D483%2F682%29%3B%20%CE%9415%25%23%20%28P%3C0.0001%29%20%28select%20secondary)

> “<sup>‡‡</sup>Rescue medication: NSAIDs, acetaminophen, and/or an antiemetic.<sup>2</sup>”

Source: [NURTEC ODT: Acute Pivotal Trial, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-pivotal-trial#:~:text=medication%3A%20NSAIDs%2C%20acetaminophen%2C%20and%2For%20an)

> “Use of Rescue Medication within 24 hours†
>
>
>
>
>    n/N*
>
>
>
> 95/669
>
>
>
> 199/682
>
>
>
>
>    % Responders
>
>
>
> 14.2
>
>
>
> 29.2
>
>
>
>
>    Difference from placebo
>
>
>
> -15.0
>
>
>
>
>    p-value
>
>
>
> <0.001”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Use%20of%20Rescue%20Medication%20within%2024%20hours%E2%80%A0,%3C0.001)

> “This analysis includes only the use of NSAIDs, acetaminophen, or antiemetics, within 24 hours post-dose; the use of triptans, or other acute migraine medication, was not allowed.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=This%20analysis%20includes%20only%20the,migraine%20medication%2C%20was%20not%20allowed.)

Note: Single 75 mg dose of Nurtec ODT compared with placebo in trial 303 (the label's Study 1, NCT03461757). The label table gives the percentage who used rescue medication; the HCP page gives the percentage who did not.

<a id="nurtec-normal-function-2-hours"></a>

### How many patients reported normal function 2 hours after Nurtec ODT?

> “Percentage of Patients Reporting Normal Function at 2 hours
>
>
>
>
>    n/N*
>
>
>
> 255/669
>
>
>
> 176/682
>
>
>
>
>    % Responders
>
>
>
> 38.1
>
>
>
> 25.8
>
>
>
>
>    Difference from placebo
>
>
>
> 12.3
>
>
>
>
>    p-value
>
>
>
> <0.001”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Percentage%20of%20Patients%20Reporting%20Normal%20Function%20at%202,%3C0.001)

> “The measurement of the percentage of patients reporting normal function at two hours after dosing was derived from a single item questionnaire, asking patients to select one response on a 4-point scale; normal function, mild impairment, severe impairment, or required bedrest.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=The%20measurement%20of%20the%20percentage,severe%20impairment%2C%20or%20required%20bedrest.)

Note: Single 75 mg dose of Nurtec ODT compared with placebo (Study 1, NCT03461757); columns are NURTEC ODT 75 mg and placebo, in that order.

<a id="nurtec-triptan-unsuitable"></a>

### Does Nurtec ODT work when triptans failed or are contraindicated (trial 406)?

> “A placebo-controlled study of Nurtec ODT in a population unsuitable for triptan use”

Source: [NURTEC ODT: Acute Triptan Unsuitable Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-triptan-unsuitable-study#:~:text=A%20placebo%2Dcontrolled%20study%20of%20Nurtec,population%20unsuitable%20for%20triptan%20use)

> “Pain freedom at 2 hours postdose<sup>1</sup>
>
> Select secondary endpoint<sup>1</sup>: 
>
> 22.7% of patients on Nurtec ODT (n=65/286) experienced pain freedom vs 7.4% on placebo (n=21/284); Δ15.3%* (P<0.0001)<sup>1</sup>”

Source: [NURTEC ODT: Acute Triptan Unsuitable Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-triptan-unsuitable-study#:~:text=Pain%20freedom%20at%202%20hours,7.4%25%20on%20placebo%20%28n%3D21%2F284%29%3B%20%CE%9415.3%25%2A)

> “Limitations: This study evaluated the efficacy of Nurtec ODT vs placebo for the acute treatment of migraine in a population of patients with contraindication(s) or prior lack of efficacy and/or tolerability to triptans. The results do not imply that rimegepant is superior to triptans. The clinical implications of the study findings may vary, as there are no agreed-upon criteria defining patients with migraine who are “triptan unsuitable.””

Source: [NURTEC ODT: Acute Triptan Unsuitable Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-triptan-unsuitable-study#:~:text=Limitations%3A%20This%20study%20evaluated%20the,migraine%20who%20are%20%E2%80%9Ctriptan%20unsuitable.%E2%80%9D)

> “Primary endpoint<sup>1,2</sup>
>
> Pain relief at 2 hours postdose”

Source: [NURTEC ODT: Acute Triptan Unsuitable Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-triptan-unsuitable-study#:~:text=Primary,relief%20at%202%20hours%20postdose)

> “**Unsuitability for triptans was defined as prior treatment failure (due to lack of efficacy or intolerance) to ≥2 triptans or the presence of a documented contraindication.<sup>1,2</sup>”

Source: [NURTEC ODT: Acute Triptan Unsuitable Study, captured 2026-11-13](https://nurtec.pfizerpro.com/acute-triptan-unsuitable-study#:~:text=%2A%2AUnsuitability%20for%20triptans%20was%20defined,the%20presence%20of%20a%20documented)

Note: Trial 406 compared Nurtec ODT with placebo in adults with a history of treatment failure with 2 or more triptans or a documented contraindication to triptans; the page footnotes refer to rimegepant 75 mg. The page labels pain freedom at 2 hours a select secondary endpoint beside the result and lists pain freedom at 2 hours among the additional secondary endpoints in its endpoint list. The result for the primary endpoint, pain relief at 2 hours, appears on the page only as a graphic and is not quoted. Trial 406 is not described in the Prescribing Information.

## Related pages
- [Medical information: Nurtec ODT (rimegepant): Acute treatment of migraine](https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine)
- [Indication](https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine/indication)
- [Safety](https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine/guidelines)
